Received Sep 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | — | IM |
Diagnosed with Lymphoma in 2019 before the vaccines and was cured in 2022 then had a relapse sometime after; This spontaneous case was reported by a consumer and describes the occurrence of FOLLICULAR LYMPHOMA RECURRENT (Diagnosed with Lymphoma in 2019 before the vaccines and was cured in 2022 then had a relapse sometime after) in a 69-year-old male patient who received SPIKEVAX NOS (SPIKEVAX NOS) for COVID-19 prophylaxis. The patient's past medical history included Follicular lymphoma from 2019 to 2022 and CAR T-cell therapy. On an unknown date, the patient received dose of SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) 1 dosage form. On an unknown date, the patient experienced FOLLICULAR LYMPHOMA RECURRENT (Diagnosed with Lymphoma in 2019 before the vaccines and was cured in 2022 then had a relapse sometime after) (seriousness criterion medically significant). At the time of the report, FOLLICULAR LYMPHOMA RECURRENT (Diagnosed with Lymphoma in 2019 before the vaccines and was cured in 2022 then had a relapse sometime after) had resolved. The action taken with SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) was unknown. For SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use), the reporter did not provide any causality assessments. Concomitant medication information was not provided. It was reported that the patient had first been diagnosed with lymphoma in 2019, before the vaccines, and was cured in 2022. He later experienced a relapse with his condition becoming particularly severe in December 2024.The patient then received treatment again and was reported to be cured. It was unknown if the patient experienced any additional symptoms or events.; Reporter's Comments: Company comment: Underlying history of follicular lymphoma is a risk factor for disease recurrence. The benefit-risk relationship of product is not affected by this report.
Medical History/Concurrent Conditions: CAR T-cell therapy; Follicular lymphoma